rawfin.tv
Pfizer Experimental Cancer Drug Fails Phase 3 Lung Cancer Study
MarketsstocksAI Generated

Pfizer Experimental Cancer Drug Fails Phase 3 Lung Cancer Study

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Pfizer's experimental cancer drug, sigvotatug vedotin, acquired through its Seagen deal, did not meet its primary endpoint in a Phase 3 lung cancer study. This clinical setback could impact Pfizer's oncology pipeline and future revenue projections.

PfizerSeagenPharmaceuticalsDrug TrialLung CancerOncology

Related Articles

Ambarella Gains as Nvidia Emerges as Potential Third Bidder

Ambarella Gains as Nvidia Emerges as Potential Third Bidder

stocks
SpaceX and Tesla Boards Review Potential $3.5 Trillion Merger

SpaceX and Tesla Boards Review Potential $3.5 Trillion Merger

stocks
Elon Musk Explores Merger Between SpaceX and Tesla

Elon Musk Explores Merger Between SpaceX and Tesla

stocks
Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks